Read this link just out from Bloomberg (5/24/21 10/32/PM EDT) along with the link in message #67, and you can see why MyMD is starting with Covid induced depression as its 1st Phase 2 trial.
I believe they are looking for MYMD-1's ability to knock down inflammation and DEPRESSION along with it, to also have a strong impact on the accompanying "LONG COVID" problems. At any rate I am sure the FDA is following this very closely and is anxious to help!